Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
64,058.39 +1,228.15 (+1.95%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
Affimed N.V. (AFMD)
| Previous close | 5.31 |
| Open | 5.42 |
| Bid | 5.31 x 100 |
| Ask | 5.55 x 100 |
| Day's range | 5.10 - 5.51 |
| 52-week range | 2.24 - 11.10 |
| Volume | |
| Avg. volume | 96,103 |
| Market cap | 82.533M |
| Beta (5Y monthly) | 2.09 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.60 |
| Earnings date | 21 May 2024 - 27 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.54 |
ZacksWall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade
The consensus price target hints at a 146.7% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GlobeNewswireAffimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster presentation MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract presenting preliminary data from the phase 2
ZacksAffimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Affimed N.V. (AFMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
